Feb 1, 2006|
FMCG: Mid-caps take centre stage...
FMCG results for the December quarter have been splendid in comparison to the same quarter the previous year. Today, we bring you an analysis of the performance of 4 mid-cap FMCG companies and reason as to why these companies are considered as the 'darlings of the markets', with every investor wanting to own them. The analysis comprises of Marico, Essel Propack, Pidilite and GSK Consumers.
Second rung FMCG companies
|Operating profit (EBDITA)
|Operating profit margin (%)
|Profit before tax
|Profit after tax
|Net profit margin (%)
|Effective tax rate
What does the study say?
The consolidated topline (4 companies combined)) grew by over 13% YoY, although slower than the 2QFY06 consolidated growth. However, the increase in expenditure was at a pace slower than the sales growth, which could be attributed to lower raw material prices like copra, vegetable fats and milk, which these companies have been witnessing for sometime now and is expected to remain on the lower side for at least another quarter, beyond which it is anyone's call as to where the prices are headed. This resulted in operating margins expanding by a strong 370 basis points. Depreciation increased by around 71% YoY, mainly because of Marico's expansion of Kaya Clinics and Essel Propack's twin acquisitions in the UK along with Marico changing its depreciation policy from straight line method to written down value method. Interest costs have increased by around 17% YoY, courtesy Essel Propack and Godrej Consumers, which had raised money to fund their respective acquisitions.
All the above factors, coupled with a considerable increase in other income, resulted in a whooping 45% YoY PAT growth for mid-cap FMCG companies. Also aiding bottomline growth was a lower tax outgo, which reduced as a percentage of PBT by 180 basis points. Mid-cap companies have set up their plants in tax havens like Baddi in Himachal Pradesh, which provide them with tax-free holidays for several years. Large companies like HLL and Britannia have also set up plants there, but not all their plants are located in such zones.
Of the 4 companies, GSK Consumers clearly stole the show with its bottomline bloating by a huge 71% YoY. However, due to rising oil prices and inability to pass on the increased costs to consumers, Essel Propack and Pidilite's margins were hit to some extent.
What to expect?
Mid-cap FMCG stocks are currently in the limelight, which has helped them close the valuation gap with their larger peers (in some cases, even higher than their peers). We believe that selective mid-cap FMCG companies are a good investment option, though their commanding valuations, as compared to the well-established larger companies, make them a somewhat risky investment proposition. Nonetheless, in our view, the smaller FMCG companies have the potential to explore the untapped markets and are already gaining acceptance.
Also, since these companies follow a different strategy by offering higher margins to wholesalers and retailers, it results in their products being pushed more than others. Further, smaller companies have started exploring rural markets, not through their own network as it is an expensive affair, but through other larger companies' networks. For example, Godrej Consumers has tied up with ITC to sell its soaps through the latter's e-Choupal network. However, the only drawback in this strategy is that of marginally lower margins, but then, in such an untapped industry, one has to go for growth, often at the cost of margins.
After having under-performed from 2001 to 2004, the FMCG sector is back on the path to recovery, with an acceleration in rural growth, increased consumer spending and a shift in product preference towards higher-end products in the FMCG sector. Also, with greater possibility of oil prices softening in the medium-term, pressure on operating margins of FMCG companies could ease.
More Views on News
Aug 9, 2017
While GST implementation brought down volumes and profitability in the short run, Marico remains optimistic in the long run.
Dec 9, 2016
Procter & Gamble Hygiene and Health Care has announced the first quarter results of the financial year ended June 2017 (1QFY17). The company's sales rose by 12.5%YoY while net profit rose by 50.1% YoY during the quarter.
Nov 30, 2016
Nestle India declared results for the quarter ended September 2016. Here is our analysis of the result.
Nov 30, 2016
GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.
Nov 28, 2016
Marico has reported a flat topline while the bottomline has grown by 18% YoY during the quarter.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407